STOCKSCOUTER
StockScouter Premium
StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance
Learn more or Get it now! Stockscouter Portfolio performance
BBIO BRIDGEBIO PHARMA INCORPORATED StockScouter® Report
1
StockScouter® Score
BRIDGEBIO PHARMA INCORPORATED, a mid cap company in the healthcare sector, is expected to underperform the market over the next six months with higher than average risk
10 is the best possible rating. Learn more.
Summary
Positives
- The multi-period measure of relative price change and consistency is above average. Positive/Neutral
Concerns
- The enterprise value-to-sales ratio is much higher than the average for comparably-sized companies in the StockScouter universe. Very Negative
- Earnings growth in the past year has decelerated rapidly compared to earnings growth in the past three years. Negative
- One or more analysts has modestly decreased quarterly earnings estimates for BBIO. Negative
Short-term Outlook
Over the next 1-2 months, StockScouter forecasts that mid cap stocks will be out of favor, stocks will be , and healthcare stocks will be out of favor.
Expected Risk/Return
Core Model Grades
F
C
F
B